Format

Send to

Choose Destination

See 1 citation found by title matching your search:

BMC Pediatr. 2017 Feb 13;17(1):53. doi: 10.1186/s12887-016-0702-y.

Bell's Palsy in Children (BellPIC): protocol for a multicentre, placebo-controlled randomized trial.

Author information

1
Department of Emergency Medicine, Royal Children's Hospital, Flemington Rd, Parkville, VIC, 3052, Australia. franz.babl@rch.org.au.
2
Murdoch Children's Research Institute, Parkville, Victoria, Australia. franz.babl@rch.org.au.
3
Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia. franz.babl@rch.org.au.
4
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
5
Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
6
Department of Neurology, Royal Children's Hospital, Parkville, VIC, Australia.
7
Princess Margaret Hospital for Children, Perth, Australia.
8
Schools of Paediatric and Child Health and Primary, Aboriginal and Rural Health Care, University of Western Australia, Perth, Western Australia, Australia.
9
Lady Cilento Children's Hospital, Brisbane, Australia.
10
University of Queensland, Brisbane, Australia.
11
Mater Research Institute, Brisbane, Australia.
12
Women's & Children's Hospital, Adelaide, Australia.
13
The Children's Hospital at Westmead, Sydney, Australia.
14
Sydney Children's Hospital, Randwick, New South Wales, Australia.
15
Department of Emergency Medicine, Royal Children's Hospital, Flemington Rd, Parkville, VIC, 3052, Australia.
16
Monash Medical Centre, Clayton, Victoria, Australia.
17
Townsville Hospital and James Cook University College of Medicine and Dentistry, Townsville, Australia.
18
Sunshine Hospital, St Albans, Victoria, Australia.
19
Gold Coast University Hospital, Southport, Queensland, Australia.
20
John Hunter Hospital, Newcastle, New South Wales, Australia.
21
Department of Anaesthesia, Royal Children's Hospital, Parkville, Victoria, Australia.
22
Department of Otolaryngology, Royal Children's Hospital, Parkville, Victoria, Australia.
23
Department of Family & Community Medicine, North York General Hospital, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
24
Pharmacy Department, Royal Children's Hospital, Parkville, Victoria, Australia.
25
Centre for Health Policy Melbourne School of Global and Population Health, The University of Melbourne, Carlton, Victoria, Australia.
26
Psychological Sciences & Paediatrics, University of Melbourne, The Royal Children's Hospital, Melbourne, VIC, Australia.
27
Starship Hospital, Auckland, New Zealand.
28
Liggins Institute, University of Auckland, Auckland, New Zealand.

Abstract

BACKGROUND:

Bell's palsy or acute idiopathic lower motor neurone facial paralysis is characterized by sudden onset paralysis or weakness of the muscles to one side of the face controlled by the facial nerve. While there is high level evidence in adults demonstrating an improvement in the rate of complete recovery of facial nerve function when treated with steroids compared with placebo, similar high level studies on the use of steroids in Bell's palsy in children are not available. The aim of this study is to assess the utility of steroids in Bell's palsy in children in a randomised placebo-controlled trial.

METHODS/DESIGN:

We are conducting a randomised, triple-blinded, placebo controlled trial of the use of prednisolone to improve recovery from Bell's palsy at 1 month. Study sites are 10 hospitals within the Australian and New Zealand PREDICT (Paediatric Research in Emergency Departments International Collaborative) research network. 540 participants will be enrolled. To be eligible patients need to be aged 6 months to < 18 years and present within 72 hours of onset of clinician diagnosed Bell's palsy to one of the participating hospital emergency departments. Patients will be excluded in case of current use of or contraindications to steroids or if there is an alternative diagnosis. Participants will receive either prednisolone 1 mg/kg/day to a maximum of 50 mg/day or taste matched placebo for 10 days. The primary outcome is complete recovery by House-Brackmann scale at 1 month. Secondary outcomes include assessment of recovery using the Sunnybrook scale, the emotional and functional wellbeing of the participants using the Pediatric Quality of Life Inventory and Child Health Utility 9D Scale, pain using Faces Pain Scale Revised or visual analogue scales, synkinesis using a synkinesis assessment questionnaire and health utilisation costs at 1, 3 and 6 months. Participants will be tracked to 12 months if not recovered earlier. Data analysis will be by intention to treat with primary outcome presented as differences in proportions and an odds ratio adjusted for site and age.

DISCUSSION:

This large multicenter randomised trial will allow the definitive assessment of the efficacy of prednisolone compared with placebo in the treatment of Bell's palsy in children.

TRIAL REGISTRATION:

The study is registered with the Australian New Zealand Clinical Trials Registry ACTRN12615000563561 (1 June 2015).

KEYWORDS:

Bell’s palsy; Child; Facial nerve palsy; House Brackmann scale; Prednisolone; Randomised controlled trial

PMID:
28193257
PMCID:
PMC5307816
DOI:
10.1186/s12887-016-0702-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center